US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
ATE95193T1
(de)
|
1987-06-17 |
1993-10-15 |
Sandoz Ag |
Cyclosporine und deren benutzung als arzneimittel.
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
JP3771253B2
(ja)
|
1988-09-02 |
2006-04-26 |
ダイアックス コープ. |
新規な結合タンパク質の生成と選択
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
WO1991010741A1
(en)
|
1990-01-12 |
1991-07-25 |
Cell Genesys, Inc. |
Generation of xenogeneic antibodies
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
WO1992020791A1
(en)
|
1990-07-10 |
1992-11-26 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
DE69133557D1
(de)
|
1990-08-29 |
2007-03-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
EP0564531B1
(en)
|
1990-12-03 |
1998-03-25 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
ES2330052T3
(es)
|
1991-03-01 |
2009-12-03 |
Dyax Corporation |
Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
EP0580737B1
(en)
|
1991-04-10 |
2004-06-16 |
The Scripps Research Institute |
Heterodimeric receptor libraries using phagemids
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
KR100254759B1
(ko)
|
1992-01-23 |
2000-05-01 |
플레믹 크리스티안 |
단량체 및 이량체 항체-단편 융합 단백질
|
DE69334255D1
(de)
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
CA2076465C
(en)
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
ATE165113T1
(de)
|
1992-05-08 |
1998-05-15 |
Creative Biomolecules Inc |
Mehrwertige chimäre proteine anologe und verfahren zu deren anwendungen
|
DK1087013T3
(da)
|
1992-08-21 |
2009-05-11 |
Univ Bruxelles |
Immunoglobuliner uden lette kæder
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
WO1994007921A1
(en)
|
1992-09-25 |
1994-04-14 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
ATE348110T1
(de)
|
1992-10-28 |
2007-01-15 |
Genentech Inc |
Hvegf rezeptor als vegf antagonist
|
EP0627932B1
(en)
|
1992-11-04 |
2002-05-08 |
City Of Hope |
Antibody construct
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
CA2150262C
(en)
|
1992-12-04 |
2008-07-08 |
Kaspar-Philipp Holliger |
Multivalent and multispecific binding proteins, their manufacture and use
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
WO1996013583A2
(en)
|
1994-10-20 |
1996-05-09 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
WO1996037621A2
(en)
|
1995-05-23 |
1996-11-28 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Multimeric proteins
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
DE69730209T2
(de)
|
1996-04-04 |
2005-04-14 |
Unilever N.V. |
Multivalentes und multispezifisches Antigenbindungsprotein
|
TW533205B
(en)
|
1996-06-25 |
2003-05-21 |
Novartis Ag |
Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
|
WO1998006842A1
(en)
|
1996-08-16 |
1998-02-19 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
PT1787999E
(pt)
|
1997-04-07 |
2010-11-11 |
Genentech Inc |
Anticorpos anti-vegf
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
EP0981548A4
(en)
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
CA2304254C
(en)
|
1997-06-11 |
2012-05-22 |
Hans Christian Thogersen |
Trimerising module
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
WO1999020758A1
(en)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
CN1203178C
(zh)
|
1997-10-27 |
2005-05-25 |
尤尼利弗公司 |
多价抗原结合蛋白
|
ES2234241T3
(es)
|
1998-01-23 |
2005-06-16 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
Derivados de anticuerpo de multiples fines.
|
JP2002502607A
(ja)
|
1998-02-09 |
2002-01-29 |
ジェネンテク・インコーポレイテッド |
新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
EP1073465B1
(en)
|
1998-04-15 |
2005-06-22 |
The Brigham And Women's Hospital, Inc. |
T cell inhibitory receptor compositions and uses thereof
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
DE69911793T2
(de)
|
1998-07-28 |
2004-08-12 |
Micromet Ag |
Heterominikörper
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
CA2378179A1
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
NZ521540A
(en)
|
2000-04-11 |
2004-09-24 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
US20020103345A1
(en)
|
2000-05-24 |
2002-08-01 |
Zhenping Zhu |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
EP1294904A1
(en)
|
2000-06-30 |
2003-03-26 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Heterodimeric fusion proteins
|
WO2002008293A2
(en)
|
2000-07-25 |
2002-01-31 |
Immunomedics Inc. |
Multivalent target binding protein
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
EP2351838A1
(en)
|
2000-10-20 |
2011-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Crosslinking agonistic antibodies
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
EP1399484B1
(en)
|
2001-06-28 |
2010-08-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
DE60124912T2
(de)
|
2001-09-14 |
2007-06-14 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, Tandem-Fv-Antikörper
|
PT1441737E
(pt)
|
2001-10-30 |
2006-12-29 |
Dana Farber Cancer Inst Inc |
Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
|
AU2002357072A1
(en)
|
2001-12-07 |
2003-06-23 |
Centocor, Inc. |
Pseudo-antibody constructs
|
CN100522967C
(zh)
|
2002-02-01 |
2009-08-05 |
阿里亚德基因治疗公司 |
含磷化合物及其应用
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
PT2275102E
(pt)
|
2002-03-13 |
2015-10-27 |
Array Biopharma Inc |
Derivados de benzimidazole alquilado n3 como inibidores de mek
|
JP4386741B2
(ja)
|
2002-04-15 |
2009-12-16 |
中外製薬株式会社 |
scDbライブラリーの作成方法
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
AU2003291002A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
EP1578419A4
(en)
|
2002-12-30 |
2008-11-12 |
3M Innovative Properties Co |
IMMUNOSTIMULATING COMBINATIONS
|
CA2515726C
(en)
|
2003-02-11 |
2012-07-10 |
Vernalis (Cambridge) Limited |
Isoxazole compounds
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
WO2004094613A2
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
CA2525717A1
(en)
|
2003-05-23 |
2004-12-09 |
Wyeth |
Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
|
ME00425B
(me)
|
2003-05-30 |
2011-10-10 |
Genentech Inc |
Liječenje sa anti-vegf antitijelima
|
EP1641827A2
(en)
|
2003-06-27 |
2006-04-05 |
Biogen Idec MA Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
WO2005004809A2
(en)
|
2003-07-01 |
2005-01-20 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
US20070142401A1
(en)
|
2003-10-27 |
2007-06-21 |
Novartis Ag |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US7932260B2
(en)
|
2004-05-13 |
2011-04-26 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
RS52670B
(en)
|
2004-06-11 |
2013-06-28 |
Japan Tobacco Inc. |
5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
ES2711213T3
(es)
|
2005-02-08 |
2019-04-30 |
Genzyme Corp |
Anticuerpos de TGFbeta
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
EP1874824A4
(en)
|
2005-04-06 |
2009-12-30 |
Ibc Pharmaceuticals Inc |
METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
|
CA2605024C
(en)
|
2005-04-15 |
2018-05-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
SI1877090T1
(sl)
|
2005-05-06 |
2014-12-31 |
Providence Health System |
Trimerni fuzijski protein OY40-imunoglobulina in postopki uporabe
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
WO2007004415A1
(ja)
|
2005-07-01 |
2007-01-11 |
Murata Manufacturing Co., Ltd. |
多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
ATE452913T1
(de)
|
2005-08-26 |
2010-01-15 |
Pls Design Gmbh |
Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
WO2007062466A1
(en)
|
2005-11-29 |
2007-06-07 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
PL2251034T3
(pl)
|
2005-12-02 |
2018-07-31 |
Icahn School Of Medicine At Mount Sinai |
Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
|
TWI468162B
(zh)
|
2005-12-13 |
2015-01-11 |
英塞特公司 |
作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶
|
PL2481753T3
(pl)
|
2005-12-13 |
2018-09-28 |
Eli Lilly And Company |
Przeciwciała anty-IL-17
|
PT2347775T
(pt)
|
2005-12-13 |
2020-07-14 |
The President And Fellows Of Harvard College |
Estruturas em andaime para transplante celular
|
EP1981969A4
(en)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
BRPI0707824A2
(pt)
|
2006-02-15 |
2011-05-10 |
Imclone Systems Inc |
proteÍna de ligaÇço a antÍgeno, e, mÉtodos de neutralizaÇço da ativaÇço de um receptor de tirosina quinase, de inibiÇço de angiogÊnese, de reduÇço de crescimento de tumor e de produÇço de uma proteÍna de ligaÇço a antÍgeno
|
WO2007109254A2
(en)
|
2006-03-17 |
2007-09-27 |
Biogen Idec Ma Inc. |
Stabilized polypeptide compositions
|
US8946391B2
(en)
|
2006-03-24 |
2015-02-03 |
The Regents Of The University Of California |
Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
JP5189082B2
(ja)
|
2006-05-25 |
2013-04-24 |
バイエル・ファルマ・アクチェンゲゼルシャフト |
二量体分子複合体
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
MX363905B
(es)
|
2006-06-12 |
2019-04-08 |
Aptevo Res & Development Llc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
PE20110224A1
(es)
|
2006-08-02 |
2011-04-05 |
Novartis Ag |
PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
|
ME00588A
(en)
|
2006-08-18 |
2011-12-20 |
|
Prlr-specific antibody and uses thereof
|
CA2661042C
(en)
|
2006-08-18 |
2012-12-11 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
MX2009001878A
(es)
|
2006-08-21 |
2009-03-03 |
Genentech Inc |
Compuestos de aza-benzofuranilo y metodos de uso.
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
JP5519287B2
(ja)
|
2006-11-02 |
2014-06-11 |
ダニエル・ジェイ・カポン |
可動部を備えたハイブリッド免疫グロブリン
|
ES2689444T3
(es)
|
2006-11-22 |
2018-11-14 |
Incyte Holdings Corporation |
Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
|
WO2008070743A2
(en)
|
2006-12-05 |
2008-06-12 |
Memgen Llc |
Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35
|
EP2091918B1
(en)
|
2006-12-08 |
2014-08-27 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
EP3222634A1
(en)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
US9770535B2
(en)
|
2007-06-21 |
2017-09-26 |
President And Fellows Of Harvard College |
Scaffolds for cell collection or elimination
|
NZ599338A
(en)
|
2007-06-27 |
2013-11-29 |
Marinepolymer Tech Inc |
Complexes of il-15 and il-15ralpha and uses thereof
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
WO2009068630A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Immunoglobulin constructs
|
US20110008345A1
(en)
|
2007-11-30 |
2011-01-13 |
Claire Ashman |
Antigen-binding constructs
|
PT2690101E
(pt)
|
2007-12-19 |
2015-10-08 |
Genentech Inc |
5-anilinoimidazopiridinas e métodos de utilização
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
US8747847B2
(en)
|
2008-02-11 |
2014-06-10 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
JP5690143B2
(ja)
|
2008-02-13 |
2015-03-25 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
持続的細胞プログラミング装置
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
AR070924A1
(es)
|
2008-03-19 |
2010-05-12 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
|
SI2300455T1
(sl)
|
2008-05-21 |
2017-12-29 |
Incyte Holdings Corporation |
Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
|
EP2282995B1
(en)
|
2008-05-23 |
2015-08-26 |
Novartis AG |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
UY31929A
(es)
|
2008-06-25 |
2010-01-05 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
MX2011000039A
(es)
|
2008-07-02 |
2011-05-31 |
Emergent Product Dev Seattle |
Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos.
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
JP5767109B2
(ja)
|
2008-07-17 |
2015-08-19 |
ノバルティス アーゲー |
治療抗体を用いる組成物及び方法
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
AR072999A1
(es)
*
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
PL2331547T3
(pl)
|
2008-08-22 |
2015-01-30 |
Novartis Ag |
Związki pirolopirymidynowe jako inhibitory CDK
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Pd-1 길항제 및 그의 사용 방법
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
CN103333157A
(zh)
|
2008-09-02 |
2013-10-02 |
诺瓦提斯公司 |
作为激酶抑制剂的吡啶甲酰胺衍生物
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
CN102227221A
(zh)
|
2008-11-28 |
2011-10-26 |
诺瓦提斯公司 |
包含hsp90抑制剂和mtor抑制剂的药物组合
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
WO2010091262A1
(en)
|
2009-02-05 |
2010-08-12 |
Mount Sinai School Of Medicine Of New York University |
Chimeric newcastle disease viruses and uses thereof
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
EP2990421B1
(en)
|
2009-04-30 |
2018-02-21 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Anti ceacam1 antibodies and methods of using same
|
MY155570A
(en)
|
2009-06-26 |
2015-10-30 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
KR101573109B1
(ko)
|
2009-11-24 |
2015-12-01 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
SG184427A1
(en)
|
2010-04-20 |
2012-11-29 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
KR101846590B1
(ko)
|
2010-06-11 |
2018-04-09 |
교와 핫꼬 기린 가부시키가이샤 |
항 tim-3 항체
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
EA036314B1
(ru)
|
2010-08-20 |
2020-10-26 |
Новартис Аг |
Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
|
MY171312A
(en)
|
2010-08-23 |
2019-10-08 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
KR20140020228A
(ko)
|
2010-09-21 |
2014-02-18 |
알토 바이오사이언스 코포레이션 |
다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
|
WO2012048165A2
(en)
|
2010-10-06 |
2012-04-12 |
President And Fellows Of Harvard College |
Injectable, pore-forming hydrogels for materials-based cell therapies
|
EP2701745B1
(en)
|
2011-04-28 |
2018-07-11 |
President and Fellows of Harvard College |
Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
|
EP2714073B1
(en)
|
2011-06-03 |
2021-03-10 |
President and Fellows of Harvard College |
In situ antigen-generating cancer vaccine
|
KR102051014B1
(ko)
|
2011-06-03 |
2019-12-04 |
조마 테크놀로지 리미티드 |
Tgf-베타에 특이적인 항체
|
WO2012177624A2
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
LT2771364T
(lt)
|
2011-10-27 |
2019-09-10 |
Genmab A/S |
Heterodimerinių baltymų gamyba
|
LT2785375T
(lt)
|
2011-11-28 |
2020-11-10 |
Merck Patent Gmbh |
Anti-pd-l1 antikūnai ir jų panaudojimas
|
CA2892371C
(en)
|
2011-12-01 |
2021-01-19 |
The Brigham And Women's Hospital, Inc. |
Anti-ceacam1 recombinant antibodies for cancer therapy
|
CN109125718A
(zh)
|
2012-01-13 |
2019-01-04 |
哈佛学院董事会 |
在结构聚合装置中tlr激动剂的控制传递
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
WO2013148228A1
(en)
|
2012-03-29 |
2013-10-03 |
Advanced Cancer Therapeutics, Llc |
Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic
|
CA2870309C
(en)
|
2012-04-16 |
2024-02-20 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
CA3085032A1
(en)
|
2012-04-17 |
2013-10-24 |
University Of Washington Through Its Center For Commercialization |
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
|
MX2014013373A
(es)
|
2012-05-15 |
2015-08-14 |
Novartis Ag |
Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
|
KR20150008406A
(ko)
|
2012-05-15 |
2015-01-22 |
노파르티스 아게 |
Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
|
AP3613A
(en)
|
2012-05-15 |
2016-02-29 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
|
PT2900637T
(pt)
|
2012-05-15 |
2017-11-15 |
Novartis Ag |
Derivados de amida de pirimidina, piridina e pirazina substituídos com tiazole ou imidazole e compostos relacionados como inibidores de abl1, abl2 e bcr-abl1 para tratamento do cancro, infecções virais específicas e disturbios do snc específicos
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
AU2013334610B2
(en)
|
2012-10-24 |
2018-09-13 |
Novartis Ag |
IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
|
CA2890663A1
(en)
|
2012-11-08 |
2014-05-15 |
Novartis Ag |
Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
JP2016501221A
(ja)
|
2012-11-28 |
2016-01-18 |
ノバルティス アーゲー |
併用療法
|
CA3185317A1
(en)
|
2013-02-08 |
2014-08-14 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
AP2015008707A0
(en)
|
2013-03-14 |
2015-09-30 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
BR112015021414B1
(pt)
|
2013-03-14 |
2020-11-10 |
Icahn School Of Medicine At Mount Sinai |
vírus da doença newcastle e seus usos
|
JP6400082B2
(ja)
|
2013-05-18 |
2018-10-03 |
アデュロ バイオテック,インコーポレイテッド |
「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
|
JP6453855B2
(ja)
|
2013-05-18 |
2019-01-16 |
アドゥロ バイオテック,インク. |
「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
KR20240056664A
(ko)
|
2013-09-11 |
2024-04-30 |
메디뮨 리미티드 |
종양 치료용 항-b7-h1 항체
|
MX355480B
(es)
|
2013-11-01 |
2018-04-19 |
Novartis Ag |
Amino-heteroaril-benzamidas como inhibidores de cinasa.
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
JOP20200094A1
(ar)
*
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
ME03558B
(me)
*
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|